Related references
Note: Only part of the references are listed.Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial
Liselotte M. S. Boeve et al.
EUROPEAN UROLOGY (2019)
Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis
Sarah Burdett et al.
EUROPEAN UROLOGY (2019)
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
Matthew Smith et al.
LANCET ONCOLOGY (2019)
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Salah-Eddin Al-Batran et al.
LANCET (2019)
Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. G. Casali et al.
ANNALS OF ONCOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Vogel et al.
ANNALS OF ONCOLOGY (2018)
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
Christopher C. Parker et al.
LANCET (2018)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos et al.
LANCET (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
ESMO-Magnitude of Clinical Benefit Scale version 1.1
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2017)
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E. C. Smyth et al.
ANNALS OF ONCOLOGY (2016)
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
Salah-Eddin Al-Batran et al.
LANCET ONCOLOGY (2016)
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
M. Ducreux et al.
ANNALS OF ONCOLOGY (2015)
Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
C. Parker et al.
ANNALS OF ONCOLOGY (2015)
Share Paper
